Clinical Trial Update: A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes [Phase 1]

View source ↗

Summary

A Phase I study evaluating 8 weeks of continuous treatment with polyethylene glycol loxenatide in patients with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PEG-Loxenatide (polyethylene glycol loxenatide)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED